Skip to content

Clinical trials

Phase 2 Nasopharyngeal Neoplasms trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Nasopharyngeal Neoplasms Phase: Phase 2 Clear all

79 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20022
20033
20042
20052
20065
20075
20081
20091
20101
20111
20121
20134
20142
20152
20166
20176
20181
20193
20201
20212
20224
20234
20245
20253
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed35
Unknown status21
Recruiting9
Terminated5
Active, not recruiting4
Not yet recruiting2
Suspended1
Enrolling by invitation1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Sun Yat-sen University15
National Cancer Institute (NCI)3
Sanofi3
Dana-Farber Cancer Institute2
Fudan University2
Hoffmann-La Roche2
Memorial Sloan Kettering Cancer Center2
National University Hospital, Singapore2
The First Affiliated Hospital of Xiamen University2
University Health Network, Toronto2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Nasopharyngeal Neoplasms79
Nasopharyngeal Carcinoma20
Head and Neck Neoplasms19
Hypopharyngeal Neoplasms11
Mouth Neoplasms11
Oropharyngeal Neoplasms11
Laryngeal Neoplasms10
Recurrence6
Carcinoma, Non-Small-Cell Lung5
Epstein-Barr Virus Infections5

Trials

Showing 1 to 25 of 79. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.